Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors

Rosell, Rafael; Pifarré, Alex; Monzó, Mariano; Astudillo, J.; López-Cabrerizo, M. Paz; Calvo, Ran; Moreno, Isabel; Sánchez-Céspedes, Montserrat; Font, Albert; Navas‐Palacios, José J.

doi:10.1002/(sici)1097-0215(19970620)74:3<330::aid-ijc17>3.0.co;2-f

Cited by 55 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Developing improved prognostic tools is important as the current array of clinical predictors provides only broad categorizations of risk and insufficiently characterizes the relative risk for recurrence in individual patients (7). As an example, patients with early stage colon cancer (stages I and II) are usually considered cured after surgical resection, despite the fact that 15-20% of these patients develop disease recurrence (8,9).…”

mentioning

confidence: 99%

RETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities

Garman¹,

Acharya²,

Grade

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Gene expression profiles provide an opportunity to dissect the heterogeneity of solid tumors, including colon cancer, to improve prognosis and predict response to therapies. Bayesian binary regression methods were used to generate a signature of disease recurrence in patients with resected early stage colon cancer validated in an independent cohort. A 50-gene signature was developed that effectively distinguished early stage colon cancer patients with a low or high risk of disease recurrence. RT-PCR analysis of the 50-gene signature validated 9 of the top 10 differentially expressed genes. When applied to two independent validation cohorts of 55 and 73 patients, the 50-gene model accurately predicted recurrence. Standard Kaplan–Meier survival analysis confirmed the prognostic accuracy ( P < 0.01, log rank), as did multivariate Cox proportional hazard models. We tested potential targeted therapeutic options for patients at high risk for disease recurrence and found a clinically important relationship between sensitivity to celecoxib, LY-294002 (PI3kinase inhibitor), retinol, and sulindac in colon cancer cell lines expressing the poor prognostic phenotype ( P < 0.01, t test), which performed better than standard chemotherapy (5-FU and oxaliplatin). We present a genomic strategy in early stage colon cancer to identify patients at highest risk of recurrence. An ability to move beyond current staging by refining the estimation of prognosis in early stage colon cancer also has implications for individualized therapy.

show abstract

mentioning

confidence: 99%

RETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities

Garman¹,

Acharya²,

Grade

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…In total, 53 publications, published between 1990 and 2003, were found eligible for the systematic review (Rodenhuis et al, 1988(Rodenhuis et al, , 1997Slebos et al, 1990;Mitsudomi et al, 1991;Miyamoto et al, 1991;Harada et al, 1992;Sugio et al, 1992;Rosell et al, 1993Rosell et al, , 1995bRosell et al, , 1996Rosell et al, , 1997Volm et al, 1993Volm et al, , 2002Westra et al, 1993;Kern et al, 1994;Li et al, 1994;Silini et al, 1994;Fujino et al, 1995;Kashii et al, 1995;Keohavong et al, 1996Keohavong et al, , 1997Cho et al, 1997;Dosaka-Akita et al, 1997;Fukuyama et al, 1997;Komiya et al, 1997;Pifarré et al, 1997;Siegfried et al, 1997;Visscher et al, 1997;De Gregorio et al, 1998;Greatens et al, 1998;Huang et al, 1998;Kim et al, 1998;Kwiatkowski et al, 1998;Nemunaitis et al, 1998;Wang et al, 1998;Dingemans et al, 1999;Fu et al, 1999;Graziano et al, 1999;Miyake et al, 1999;Nelson et al, 1999;Hommura et al, 2000;…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

et al. 2004

View full text Add to dashboard Cite

The proto-oncogene RAS, coding for a 21 kDa protein (p21), is mutated in 20% of lung cancer. However, the literature remains controversial on its prognostic significance for survival in lung cancer. We performed a systematic review of the literature with metaanalysis to assess its possible prognostic value on survival. Published studies on lung cancer assessing prognostic value of RAS mutation or p21 overexpression on survival were identified by an electronic search. After a methodological assessment, we estimated individual hazard ratios (HR) estimating RAS protein alteration or RAS mutation effect on survival and combined them using metaanalytic methods. In total, 53 studies were found eligible, with 10 concerning the same cohorts of patients. Among the 43 remaining studies, the revelation method was immunohistochemistry (IHC) in nine and polymerase chain reaction (PCR) in 34. Results in terms of survival were significantly pejorative, significantly favourable, not significant and not conclusive in 9, 1, 31, 2, respectively. In total, 29 studies were evaluable for meta-analysis but we aggregated only the 28 dealing with non-small-cell lung cancer (NSCLC) and not the only one dealing with small-cell-lung cancer (SCLC). The quality scores were not statistically significantly different between studies with or without significant results in terms of survival, allowing us to perform a quantitative aggregation. The combined HR was 1.35 (95% CI: 1.16 -1.56), showing a worse survival for NSCLC with KRAS2 mutations or p21 overexpression and, particularly, in adenocarcinomas (ADC) (HR 1.59; 95% CI 1.26 -2.02) and in studies using PCR (HR 1.40; 95% CI 1.18 -1.65) but not in studies using IHC (HR 1.08; 95% CI 0.86 -1.34). RAS appears to be a pejorative prognostic factor in terms of survival in NSCLC globally, in ADC and when it is studied by PCR.

show abstract

“…Although prognosis in general correlates with clinical variables, such as stage, it is currently difficult to predict the clinical outcome for individual patients with stage I tumors (3). Several molecular prognostic factors have been proposed, such as K-ras or p53 mutational status, Bcl-2 and c-erbB-2 overexpression (4), and DNA replication errors manifested as microsatellite instability (5). Given the known morphologic and molecular heterogeneity of lung carcinomas and the complex nature of treatment responses, analysis of multiple biologic or molecular markers may be more informative than any single marker (6,7).…”

mentioning

confidence: 99%

Protein profiles associated with survival in lung adenocarcinoma

Chen

Gharib

Wang

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

261

188

View full text Add to dashboard Cite

Morphologic assessment of lung tumors is informative but insufficient to adequately predict patient outcome. We previously identified transcriptional profiles that predict patient survival, and here we identify proteins associated with patient survival in lung adenocarcinoma. A total of 682 individual protein spots were quantified in 90 lung adenocarcinomas by using quantitative two-dimensional polyacrylamide gel electrophoresis analysis. A leave-one-out cross-validation procedure using the top 20 survivalassociated proteins identified by Cox modeling indicated that protein profiles as a whole can predict survival in stage I tumor patients (P ‫؍‬ 0.01). Thirty-three of 46 survival-associated proteins were identified by using mass spectrometry. Expression of 12 candidate proteins was confirmed as tumor-derived with immunohistochemical analysis and tissue microarrays. Oligonucleotide microarray results from both the same tumors and from an independent study showed mRNAs associated with survival for 11 of 27 encoded genes. Combined analysis of protein and mRNA data revealed 11 components of the glycolysis pathway as associated with poor survival. Among these candidates, phosphoglycerate kinase 1 was associated with survival in the protein study, in both mRNA studies and in an independent validation set of 117 adenocarcinomas and squamous lung tumors using tissue microarrays. Elevated levels of phosphoglycerate kinase 1 in the serum were also significantly correlated with poor outcome in a validation set of 107 patients with lung adenocarcinomas using ELISA analysis. These studies identify new prognostic biomarkers and indicate that protein expression profiles can predict the outcome of patients with early-stage lung cancer.

show abstract

Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors

Cited by 55 publications

References 20 publications

RETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities

RETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

Protein profiles associated with survival in lung adenocarcinoma

Contact Info

Product

Resources

About